Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3741-3760 of 3,900 trials

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyOphthalmology

Head and Neck Cancer: NBTXR3 Treatment Study

We are studying a new treatment involving NBTXR3 with or without cetuximab for elderly patients with locally advanced head and neck cancer. The goal is to see if this approach improves survival compared to standard radiotherapy.

Head and Neck Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Spinocerebellar Ataxia SCA27B: Fampridine Study

We are investigating whether fampridine can help improve movement and daily activities in patients with spinocerebellar ataxia SCA27B. This study will also assess its effects on quality of life and overall health.

Spinocerebellar Ataxia1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineNeurology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

REM0045392: New Medication Study

We are investigating a new medication to see how safe and effective it is compared to a placebo in healthy individuals. This study will help us understand its potential benefits and risks.

Alzheimer's Disease1-2 yearsSafety phase (I)Neurology

Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

Heart Attack6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePulmonology

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Haemophilia A: Inno8 Medication Study

We are researching how different doses of the medication Inno8 work in people with haemophilia A. This study aims to understand its effects on the body.

Haemophilia A6-12 monthsSafety phase (I)Hematology

Neurogenic Inflammation: TRPA1 Activation Study

We are investigating how a specific compound affects inflammation in people with conditions related to nerve pain. This research may help us understand better ways to manage pain and inflammation.

Healthy Participants3-6 monthsSafety phase (I)

Platysma Prominence: NT 201 Treatment Study

We are investigating whether NT 201 can safely reduce moderate to severe platysma prominence in adults compared to a placebo. This study aims to find out if this treatment can improve appearance and confidence.

Moderate to Severe Platysma Prominence3-6 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesDermatology

Asthma Treatment: AMG 691 Study

We are testing a new medication called AMG 691 in healthy individuals and those with mild-to-moderate asthma. The goal is to see how it compares to a placebo in managing asthma symptoms.

Asthma1-2 yearsSafety phase (I)Internal MedicinePulmonology

Plaque Psoriasis and Eczema: RLS-1496 Cream

We are testing a new topical cream for patients with plaque psoriasis or eczema. The goal is to see how safe it is and how well it works compared to existing treatments.

Atopic DermatitisPsoriasis6-12 monthsSafety phase (I)AllergologyDermatology

Heart Disease: AZD0780 Medication Study

We are testing whether AZD0780 can help reduce serious heart and vascular problems in patients with existing heart disease or those at high risk. This study compares AZD0780 to a placebo to see which is more effective.

Atherosclerotic Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

High 'Bad' Cholesterol: AZD0780 Study

We are investigating how well AZD0780 works for adults with high LDL cholesterol and heart disease or at risk for it. The goal is to see if it can lower cholesterol levels more effectively than a placebo.

High CholesterolAtherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Kidney Transplant: Reduced Immunosuppression for Older Adults

We are studying whether a lower dose of immunosuppressive medication is as effective and safe as the standard dose for older adults after kidney transplantation. This may help improve their overall health and quality of life.

End-stage Renal Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Major Depressive Disorder: NBI-1065845 Treatment Study

We are evaluating a new medication to see if it helps maintain improvement in people with Major Depressive Disorder. This study looks at its effects on depressive symptoms and overall functioning.

Major Depressive DisorderConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Solid Tumors: SNV1521 Treatment Study

We are exploring a new treatment called SNV1521 for individuals with advanced solid tumors. This study aims to determine the safety and appropriate dosage of this medication.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

PF-07940369: Tolerance Study in Healthy Adults

We are investigating how well different amounts of the medicine PF-07940369 are tolerated by healthy adults. This study will help us understand its effects in the body.

Clonal Hematopoiesis6-12 monthsSafety phase (I)Hematology